ELF3/ESE-1 Antibody - BSA Free

Immunohistochemistry-Paraffin: ELF3/ESE-1 Antibody [NBP1-30873]

Immunohistochemistry-Paraffin: ELF3/ESE-1 Antibody [NBP1-30873] - NCI-N87 xenograft, using ESE1 antibody at 1:100 dilution. Antigen Retrieval: Trilogy™ (EDTA based, pH 8.0) buffer, 15min.

Chromatin Immunoprecipitation: ELF3/ESE-1 Antibody [NBP1-30873] -

Chromatin Immunoprecipitation: ELF3/ESE-1 Antibody [NBP1-30873] - The transcription factor ELF3 regulates the Grhl3 promoter. (A) The sequence of the Grhl3 promoter (1000 bp) showing the location of the predicted TATA box, SP1 sequence, & the transcription start site. Sequences in red represent the conserved regions, & green bases represent putative ELF3 binding sites. (B) Luciferase reporter assay showing the activation of the Grhl3 promoter by ELF3. Relative luciferase activity is calculated as fold induction relative to vector. Drawings on the left side show a schematic representation of the Grhl3 promoter region (top) & the structure of each reporter plasmid (below). The conserved regions are shown as horizontal boxes labeled 1,2 & 3, the restriction enzymes used to generate the reporter deletions of the promoter are labeled. (C) ELF3 binding at the promoter of Grhl3. NMuMG cells were treated with either vehicle or TGF beta 3 for 72 h, TGF beta 3 treated cells were then washed with PBS & continued incubation for an additional 48 h to initiate MET (post-treatment: PT48). Cells were cross-linked, & chromatin immunoprecipitation was performed. ChIP DNA was used in qPCR to measure the occupancy of ELF3 compared to control antibodies. (D) Sequence alignment of one putative ELF3 binding site in the Grhl3 promoter showing conservation among different species. In B & C, data represent the averages of at least three independent experiments. The paired Student’s t-test was used to calculate statistical significance. ** p-value < 0.01; **** p-value < 0.0001. Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/31404945), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: ELF3/ESE-1 Antibody [NBP1-30873] -

Western Blot: ELF3/ESE-1 Antibody [NBP1-30873] - Various whole cell extracts (30 ug) were separated by 10% SDS-PAGE, and the membrane was blotted with ESE1 antibody [C2C3], C-term diluted at 1:1000. The HRP-conjugated anti-rabbit IgG antibody was used to detect the primary antibody. Corresponding RNA expression data for the same cell lines are based on Human Protein Atlas program.

Immunohistochemistry: ELF3/ESE-1 Antibody - BSA Free [NBP1-30873] -

SET8 decrease and ELF3 increase were confirmed in diabetic patients and rats.a The mRNA expression of SET8 was examined by qPCR in PBMCs from diabetic patients and healthy controls (con: n = 30, DM: n = 50). b The mRNA expression of ELF3 was examined by qPCR in PBMCs from diabetic patients and healthy controls (con: n = 30, DM: n = 50). c Results from western blot analysis of ELF3 and SET8 expression in PBMCs from diabetic patients and heathy controls (con: n = 30, DM: n = 50). d The mRNA expression of SET8 was examined by qPCR in aorta tissues from the control group and diabetic group in rats (n = 5/group). e The mRNA expression of ELF3 was examined by qPCR in aorta tissues from the control group and diabetic group in rats (n = 5/group). f Results from western blot analysis of ELF3 and SET8 expression in aorta tissues from the control group and diabetic group in rats (n = 5/group). g Immunostaining of SET8 and ELF3 in aorta tissues from the control group and diabetic group (n = 5/group). Scale bar, 50 μm. h Schematic representation of the working model. High glucose mediated NLRP3 inflammasome activation via upregulation of MARK4 expression in vascular endothelial cells. Moreover, high glucose increased ELF3 expression while inhibiting SET8 expression. Furthermore, ELF3 interacted with SET8 to modulate MARK4 expression, which was involved in the high glucose-mediated endothelial inflammasome activation in hyperglycaemic HUVECs. (*P ≤ 0.001, **P ≤ 0.0001, compared with the control group). Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/32439949), licensed under a CC-BY license. Not internally tested by Novus Biologicals.